Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Oncology Consultations™: How Do The Experts Utilize PARP Inhibitors in Ovarian Cancer Across Lines of Care?
Release Date: December 22, 2021
Expiration Date: December 22, 2022
Acknowledgement of Commercial SupportThis activity is supported by an educational grant from GlaxoSmithKline.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
Upon successful completion of this activity, you should be better prepared to:
- Analyze evidence from clinical trials that have evaluated PARP inhibitors for patients with ovarian cancer across lines of care
- Explain the rationale for PARP inhibitor-based strategies to personalize care in the maintenance setting
- Understand the role of molecular testing and its application in selecting therapy for patients with ovarian cancer
- Apply strategies for the recognition and management of adverse events associated with PARP inhibitors and other agents in ovarian cancer
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Virginia Kerley Cade Chair in Cancer Clinical Trials
Associate Director, Clinical Research
Director Phase 1 Clinical Research
Stephenson Cancer Center
Oklahoma City, OK
Disclosures: Grant/Research Support: PTC Therapeutics, Lilly, Merck, GSK/Tesaro, Verastem Oncology. Consultant: Astra Zeneca, GSK, I-Mab Biopharma, Amgen. Other Support: Advisory boards: Alkermes, AstraZeneca, Aravive, Blueprint Medicines, Eisai Co., Elevar Therapeutics, GSK/Tesaro, Genentech/Roche, Jiangsu Hengrui Pharmacuticals, I-Mab Biopharma, ImmunoGen, EQRx, Mereo, Mersana Therapeutics, Merck, Myriad Genetics, Novartis, OncXerna Therapeutics, Onconova Therapeutics, Sorrento Therapeutics, Tarveda Therapeutics, VBL Therapeutics.
Department of Obstetrics/Gynecology
University of California Los Angeles
Los Angeles, CA
Disclosures: Consultant: GSK, Merck, Instil Bio, Arcus Biosciences, Seagen, Regeneron, Genentech.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.